FDA Grants Accelerated Approval for POLIVY™
On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval for POLIVY™ (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least 2 prior therapies.
POLIVY Access Solutions is your resource for access and reimbursement support after POLIVY is prescribed. We can help your patients and practice by providing:
· Benefits investigations (BIs)
· Prior authorization (PA) resources
· Information about authorized specialty distributors
· Sample billing and coding information
· Resources for appeals
· Referrals to co-pay support
· Patient assistance options
A list of authorized specialty distributors is available at Genentech-Access.com/POLIVY
Resources: